Abstract:Abstract Background : N6-methyladenosine (m 6 A) has emerged as a significant regulator of the progress of various cancers. However, its role in lung adenocarcinoma (LUAD) remains unclear. Here, we explored the biological function and underlying mechanism of methyltransferase-like 3 (METTL3), the main catalyst of m 6 A, in LUAD progression. Methods : The expression of m 6 A, METTL3, YTHDF1 and SLC7A11 were detected by immunochemistry or/and online datasets in LUAD patients. The effects of METTL3 on LUAD cell proliferation, apoptosis and ferroptosis were assessed through in vitro loss-and gain-of-function experiments. The in vivo effect on tumorigenesis of METTL3 was evaluated using the LUAD cell xenograft mouse model. MeRIP-seq, RNA immunoprecipitation and RNA stability assay were conducted to explore the molecular mechanism of METTL3 in LUAD. Results : The results showed that the m 6 A level, as well as the methylase METTL3 were both significantly elevated in LUAD patients and lung cancer cells. Functionally, we found that METTL3 could promote proliferation and inhibit ferroptosis in different LUAD cell models, while METTL3 knockdown suppressed LUAD growth in cell-derived xenografts. Mechanistically, solute carrier 7A11 (SLC7A11), the subunit of system Xc - , was identified as the direct target of METTL3 by mRNA-seq and MeRIP-seq. METTL3-mediated m 6 A modification could stabilize SLC7A11 mRNA and promote its translation, thus promoting LUAD cell proliferation and inhibiting cell ferroptosis, a novel form of programmed cell death. Additionally, we demonstrated that YTHDF1, a m 6 A reader, was recruited by METTL3 to enhance SLC7A11 m 6 A modification. Moreover, the expression of YTHDF1 and SLC7A11 were positively correlated with METTL3 and m 6 A in LUAD tissues. Conclusions : These findings reinforced the oncogenic role of METTL3 in LUAD progression and revealed its underlying correlation with cancer cell ferroptosis; these findings also indicate that METTL3 is a promising novel target in LUAD diagnosis and therapy.

METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy

The m6A Methyltransferase METTL3 Promotes Cisplatin Resistance and Invasion in Testicular Seminoma via BCL2

Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m6A-YTHDF1-dependent manner

Methyltransferase-like 3 upregulation is involved in the chemoresistance of non-small cell lung cancer

Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy

Methyltransferase-like 3 Promotes Cervical Cancer Metastasis by Enhancing Cathepsin L Mrna Stability in an N6-methyladenosine-dependent Manner

The molecular mechanism of METTL3 promoting the malignant progression of lung cancer

The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene

M6a Methyltransferase METTL3 Promotes Non-Small-cell Lung Carcinoma Progression by Inhibiting the RIG-I-MAVS Innate Immune Pathway

METTL3 Promotes Lung Adenocarcinoma Tumorigenesis and Inhibits Ferroptosis by Stabilizing SLC7A11 m6A Modification

The two-faced role of RNA methyltransferase METTL3 on cellular response to cisplatin in head and neck squamous cell carcinoma in vitro model

METTL3 drives NSCLC metastasis by enhancing CYP19A1 translation and oestrogen synthesis

METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m6A modification

METTL3 Mediates Chemoresistance by Enhancing AML Homing and Engraftment Via ITGA4.

Association between methyltransferase-like 3 and non-small cell lung cancer: pathogenesis, therapeutic resistance, and clinical applications

METTL3-mediated m6A modification promotes chemoresistance of intrahepatic cholangiocarcinoma by up-regulating NRF2 to inhibit ferroptosis in cisplatin-resistant cells

Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway

METTL3 -mediated m6A modification of circ_0000620 regulates cisplatin sensitivity and apoptosis in lung adenocarcinoma via the MiR-216b-5p/KRAS axis

METTL3-mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway

Unraveling the independent role of METTL3 in m6A modification and tumor progression in esophageal squamous cell carcinoma

SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk